Article Text

Download PDFPDF
Diagnostic accuracy of venous system ultrasound for subtypes of acute kidney injury
  1. Mehmet Ali Aslaner1,
  2. Özant Helvacı2,
  3. Korbin Haycock3,4,
  4. İsa Kılıçaslan1,
  5. Emre Yaşar2,
  6. Mahi Nur Cerit5,
  7. Halit Nahit Şendur5,
  8. Galip Güz2,
  9. Ahmet Demircan1
  1. 1 Department of Emergency Medicine, Gazi University Faculty of Medicine, Ankara, Turkey
  2. 2 Department of Nephrology, Gazi University Faculty of Medicine, Ankara, Turkey
  3. 3 Department of Emergency Medicine, Loma Linda University, Loma Linda, California, USA
  4. 4 Emergency Medicine, Riverside University Health System, Moreno Valley, California, USA
  5. 5 Department of Radiology, Gazi University Faculty of Medicine, Ankara, Turkey
  1. Correspondence to Dr Mehmet Ali Aslaner, Department of Emergency Medicine, Gazi University Faculty of Medicine, Ankara 06560, Turkey; maliaslaner{at}hotmail.com

Abstract

Background Management of acute kidney injury (AKI) in the ED can be difficult due to uncertainty regarding the aetiology. This study investigated the diagnostic value of venous system ultrasound for determining the aetiological subtypes of AKI in the ED.

Methods This multidisciplinary prospective cohort study was conducted in a single academic ED over the course of a year. Adult patients with AKI were evaluated using the venous excess ultrasound (VExUS) score, which is a four-step ultrasound protocol. The protocol begins with the inferior vena cava (IVC) measurement and examines organ flow patterns, including portal, hepatic and renal veins in the presence of dilated IVC. The AKI subtypes (hypovolaemia, cardiorenal, systemic vasodilatation and renal) were adjudicated by nephrologists and emergency physicians, considering data that became available during the hospitalisation. We determined the diagnostic test characteristics of VExUS for identifying each of the four AKI aetiological subtypes.

Results 150 patients with AKI were included in the study. Hypovolaemia was the most frequent finally adjudicated cause of AKI (66%), followed by cardiorenal (18%), systemic vasodilatation (8.7%) and renal (7.3%). In diagnosing the cardiorenal subtype, the area under the curve (AUC) for VExUS grade >0 was 0.819, with 77.8% sensitivity and 80.5% specificity, and the AUC for IVC maximum diameter >20.4 mm was 0.865, with 74.1% sensitivity and 86.2% specificity. For the hypovolaemia subtype, the AUC for VExUS grade ≤0 was 0.711, with 83.8% sensitivity and 56.9% specificity, and the AUC for IVC maximum diameter ≤16.8 mm was 0.736, with 73.7% sensitivity and 68.6% specificity. None of the parameters achieved adequate test characteristics for renal and systemic vasodilatation subtypes.

Conclusion The VExUS score has good diagnostic accuracy for cardiorenal AKI and fair accuracy for hypovolaemic AKI but cannot identify renal and systemic vasodilatation subtypes. It should not therefore be used in isolation to determine the cause of AKI in the ED.

Trial registration number NCT04948710.

  • emergency department
  • renal
  • heart failure
  • diagnosis
  • Ultrasonography

Data availability statement

Data are available upon reasonable request. The data underlying this article will be shared on reasonable request to the corresponding author.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available upon reasonable request. The data underlying this article will be shared on reasonable request to the corresponding author.

View Full Text

Footnotes

  • Handling editor David Metcalfe

  • X @CappadociaEM

  • Contributors Research idea and study design: MAA, EY. Data acquisition: MAA. Data analysis/interpretation: MAA, ÖH, KH, İK, EY, MC, HŞ. Statistical analysis: MAA. Manuscript drafting: MAA, ÖH, KH, İK, MC, HŞ, GG, AD. Supervision or mentorship: GG, AD. MAA is guarantor.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.